Cumberland Pharmaceuticals Inc.
CPIX Nasdaq
SEC CIK 1087294
Follow Cumberland Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$2.2M
−74% vs same quarter last year
Net income
$77.8M
+4107.5% vs same quarter last year
EPS, diluted
$5.07
+4000% vs same quarter last year
Operating cash flow
−$1.5M
−900.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $44.5M | −$2.8M |
| FY24 | $37.9M | −$6.5M |
| FY23 | $39.6M | −$6.3M |
| FY22 | $42M | −$5.6M |
| FY21 | $35M | −$3.5M |
| FY20 | $35.8M | −$3.3M |
| FY19 | $32.4M | −$3.5M |
| FY18 | $28.8M | −$7M |
| FY17 | $25.5M | −$8M |
| FY16 | $32.5M | −$944.7K |
| FY15 | $900K | $731.4K |
| FY14 | $600K | $2.4M |
| FY13 | $800K | −$2.1M |
| FY12 | $700K | $5.8M |
| FY11 | $51.1M | $5.7M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 85% | −6.3% | −6.4% |
| FY24 | 82.6% | −17% | −17.1% |
| FY23 | 84.7% | −24.2% | −15.9% |
| FY22 | 78.3% | −13.6% | −13.3% |
| FY21 | 74.9% | −21.9% | −10% |
| FY20 | 75.9% | −17.8% | −9.3% |
| FY19 | 77.1% | −28.7% | −10.9% |
| FY18 | 79.1% | −38.8% | −24.2% |
| FY17 | 78.8% | −34.8% | −31.2% |
| FY16 | 81.7% | −4.4% | −2.9% |
| FY15 | - | 123.5% | 81.3% |
| FY14 | - | 593.1% | 404% |
| FY13 | - | −475.2% | −263.1% |
| FY12 | - | 1259.7% | 834.6% |
| FY11 | 89.5% | 19.3% | 11.1% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $4.8M |
| FY24 | −$678.6K |
| FY23 | $5.8M |
| FY22 | $8.4M |
| FY21 | $6.2M |
| FY20 | $5.3M |
| FY19 | $2.8M |
| FY18 | $2.7M |
| FY17 | −$833.7K |
| FY16 | $438.6K |
| FY15 | $5.7M |
| FY14 | $6.5M |
| FY13 | $648.7K |
| FY12 | $6.7M |
| FY11 | $8.5M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $263.5K |
| FY24 | $579K |
| FY23 | $740.5K |
| FY22 | $1.1M |
| FY21 | $1.4M |
| FY20 | $1.9M |
| FY19 | $3.5M |
| FY18 | $2.9M |
| FY17 | $3.7M |
| FY16 | $2.5M |
| FY15 | $5.3M |
| FY14 | $4.3M |
| FY13 | $4.8M |
| FY12 | $8.1M |
| FY11 | $4.2M |
- Cumberland Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Cumberland Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −6.4% | −30.6% |
| FY24 | −17.1% | −47% |
| FY23 | −15.9% | −58% |
| FY22 | −13.3% | −80.4% |
| FY21 | −10% | −71.8% |
| FY20 | −9.3% | −62.2% |
| FY19 | −10.9% | −46.2% |
| FY18 | −24.2% | −49.6% |
| FY17 | −31.2% | −45.9% |
| FY16 | −2.9% | −36% |
| FY15 | 81.3% | −37.8% |
| FY14 | 404% | −35.5% |
| FY13 | −263.1% | −37.1% |
| FY12 | 834.6% | −29.1% |
| FY11 | 11.1% | −27.9% |